Novartis CEO projects 2026 growth despite ‘largest patent expiry’ in company history Novartis CEO Vas Narasimhan is doubling down on a growth forecast for 2026, even as the Swiss drugmaker’s fourth-quarter

#Novartis #VasNarasimhan #patentexpirations #patentcliff #Entresto #Pluvicto #Kisqali #BTKinhibitors #PSMAtargetedradioligandtherapy #prostatecancer #BTKinhibitor #chronicspontaneousurticaria #multiplesclerosis #Rhapsido #relapsingMS #MS #antibodies #Bcellpathways #Kesimpta
zurl.co/n0N8z

Cardiovascular Safety of Bruton Tyrosine Kinase Inhibitors: From Ibrutinib to Next-Generation Agents Delve into the evolving landscape of cardiovascular toxicity related to Bruton tyrosine kinase inhibitors, from first-generation drugs to next-generation agents that have improved safety profiles.

Delve into the evolving landscape of cardiovascular toxicity related to #BTKInhibitors, from first-generation drugs to next-generation agents that have improved safety profiles.

👉 buff.ly/4FkXfDt

#OncSky #HemOnc

Hematology Weekly News – August 4th 2025 🔬🧬 Hematology Updates: Sanofi’s Myeloma Win, AI in Lymphoma, SCD Breakthrough and More From FDA orphan designations to AI-driven treatment […] The post Hematology Weekly News – August 4th 2025 appeared first on LucidQuest Ventures.

FYI: LucidQuest Views >>> Hematology Weekly News – August 4th 2025 #News #AIinhealthcare #AML #BTKInhibitors #CLL Comment below!

Hematology Weekly News – August 4th 2025 🔬🧬 Hematology Updates: Sanofi’s Myeloma Win, AI in Lymphoma, SCD Breakthrough and More From FDA orphan designations to AI-driven treatment […] The post Hematology Weekly News – August 4th 2025 appeared first on LucidQuest Ventures.

ICYMI: LucidQuest Views >>> Hematology Weekly News – August 4th 2025 #News #AIinhealthcare #AML #BTKInhibitors #CLL Comment below!

Hematology Weekly News – August 4th 2025 🔬🧬 Hematology Updates: Sanofi’s Myeloma Win, AI in Lymphoma, SCD Breakthrough and More From FDA orphan designations to AI-driven treatment […] The post Hematology Weekly News – August 4th 2025 appeared first on LucidQuest Ventures.

LucidQuest Views >>> Hematology Weekly News – August 4th 2025 #News #AIinhealthcare #AML #BTKInhibitors #CLL Comment below!

Vincent Rajkumar: Incredible Story of How Ibrutinib Came About in CLL by Jeff Sharman - OncoDaily Vincent Rajkumar shares Jeff Sharman’s thread detailing the origins of BTK inhibitor ibrutinib in treating CLL.

Incredible Story of How Ibrutinib Came About in CLL by Jeff Sharman - Vincent Rajkumar
@vincentrk.bsky.social

oncodaily.com/insight/ibru...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Ibrutinib #CLL #BTKInhibitors #Leukemia #Hematology

#LeukemiaAwareness #BloodCancer #Hematology #Oncology #CancerResearch #CLLTreatment #PrecisionMedicine #TargetedTherapy #Immunotherapy #BTKinhibitors #CAR-T #GeneTherapy #ClinicalTrials #CancerCare #HematologicMalignancies #CLLWarrior

MDADI MDADI

Drs. Meghan C. Thompson, Spencer H. Bachow, and Krish Patel discuss how they utilize non-covalent #BTKinhibitors and cellular therapies in their practices in this engaging case-based #mededsky video: bit.ly/3VxgBNt.
This activity has been developed in collaboration with the #CLLSociety. #Oncsky